<DOC>
	<DOCNO>NCT01396655</DOCNO>
	<brief_summary>Prognostic factor locally advance breast cancer treat neoadjuvant chemotherapy differ early breast cancer . The purpose study identify clinical significance potential predictive prognostic factor include serial FDG PET/CT breast cancer patient treat neoadjuvant chemotherapy .</brief_summary>
	<brief_title>PET Breast Cancer Receiving Neoadjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1. pathologicallyconfirmed breast cancer core needle biopsy , 2. initial clinical stage II III , 3. objective measurable lesion , 4 . ECOG performance 0~2 , 5. previously untreated , 6. adequate bone marrow , hepatic , cardiac , renal function 7. age 20~70 8. agreement trial , write informed consent 1. history cancer 2. active infection 3. pregnancy 4. psychologic disease 5. uncontrolled heart diseases 6. male</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>molecular marker</keyword>
	<keyword>FDG PET</keyword>
	<keyword>locally advanced breast cancer</keyword>
</DOC>